Categories
· Health/Science
· Lung Cancer
· Diabetes
|
Jump to full article: PR Newswire, 2008-04-10
Author: SOURCE MannKind Corporation
Intro: MannKind
Corporation (Nasdaq: MNKD) released the following statement in response to
the announcement by Pfizer Inc. that over the course of Exubera's clinical
trial program, 6 of the 4,740 patients treated with Exubera developed lung
cancer, although Pfizer concluded that there were too few cases to
determine whether this observation was related to Exubera. According to
Pfizer's "Dear Doctor" letter, Exubera remains a safe and effective
medication. It is important to note that each of the patients affected had
a history of cigarette smoking, a known, major risk factor for lung cancer.
Although the sugar-based Exubera formulation did have a small but
statistically significant impact on pulmonary function, we are not aware of
any specific carcinogenicity studies of Exubera to evaluate the potential
of cancer risk.
Jump to full article » |